Swiss National Bank Sells 22,100 Shares of Roivant Sciences Ltd. $ROIV

Swiss National Bank lowered its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 3.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 705,146 shares of the company's stock after selling 22,100 shares during the period. Swiss National Bank owned approximately 0.10% of Roivant Sciences worth $7,115,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Roivant Sciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 17,110 shares of the company's stock valued at $173,000 after acquiring an additional 1,434 shares during the period. CenterBook Partners LP bought a new position in Roivant Sciences during the 1st quarter valued at about $1,531,000. Charles Schwab Investment Management Inc. lifted its stake in Roivant Sciences by 1.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,847,625 shares of the company's stock valued at $28,733,000 after acquiring an additional 35,123 shares during the period. New Age Alpha Advisors LLC lifted its stake in Roivant Sciences by 37.1% during the 1st quarter. New Age Alpha Advisors LLC now owns 21,966 shares of the company's stock valued at $222,000 after acquiring an additional 5,943 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in Roivant Sciences by 44.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company's stock valued at $103,000 after acquiring an additional 3,169 shares during the period. Institutional investors own 64.76% of the company's stock.

Analyst Upgrades and Downgrades

ROIV has been the topic of several recent research reports. The Goldman Sachs Group upgraded shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 price objective on the stock in a research note on Thursday, July 10th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, June 18th.

Roivant Sciences Stock Up 0.9%

Shares of NASDAQ:ROIV opened at $11.85 on Monday. The firm's 50 day moving average price is $11.38 and its 200-day moving average price is $10.89. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06. The stock has a market capitalization of $8.06 billion, a PE ratio of -16.93 and a beta of 1.15.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). Roivant Sciences had a negative return on equity of 15.90% and a negative net margin of 2,111.79%. The business had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. During the same quarter last year, the company earned ($0.23) EPS. Analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $11.52, for a total transaction of $1,152,000.00. Following the sale, the chief executive officer owned 1,462,223 shares in the company, valued at approximately $16,844,808.96. This trade represents a 6.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the sale, the insider owned 37,284,108 shares in the company, valued at approximately $427,275,877.68. The trade was a 1.52% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,190,503 shares of company stock worth $36,086,546. 10.80% of the stock is owned by company insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.